

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

- 1.(original) The PTPRK_{Gly677→Arg682} immunogenic peptide of SEQ ID N. 1.
- 2.(original) A monoclonal or polyclonal antibody, or an active fragment thereof, which selectively binds the peptide of claim 1.
- 3.(original) An isolated nucleic acid molecule encoding the peptide of claim 1.
- 4.(original) An expression vector carrying the nucleic acid molecule of claim 3.
- 5.(original) A host cell containing the vector of claim 4.
- 6.(original) An isolated CD4+ T lymphocyte able to selectively recognize and bind the peptide SEQ ID N. 1 associated to a HLA-Class II molecule.
- 7.(original) A T lymphocyte according to claim 6, which selectively recognizes and binds a peptide/HLA-DR $\beta 1^*1001$ complex.
- 8.(original) Antigen presenting cells carrying the peptide SEQ ID N. 1 bound to a HLA-DR $\beta 1^*1001$ molecule.

9.(original) Pharmaceutical composition containing the peptide SEQ ID N. 1 or a nucleic acid molecule encoding it, in admixture with pharmaceutically acceptable excipients.

10.(original) The pharmaceutical composition of claim 9, in the form of a vaccine.

11.(currently amended) ~~The use of the~~ A medicament for the preventive or therapeutic treatment of cancer comprising one of peptide SEQ ID N. 1 and ~~[[of]] nucleic acid molecules encoding it of APCs according to claim 8 or T lymphocytes according to claims 6-7, for the preparation of a medicament for the preventive or therapeutic treatment of cancer.~~

12.(currently amended) The ~~[[use]]~~ medicament claimed in claim 11, for the preventive or therapeutic treatment of melanoma expressing PTPRK_{Gly677→Arg682}.

13.(currently amended) ~~The use of~~ A diagnostic composition comprising peptide SEQ ID N. 1 or of a nucleic acid molecule encoding it ~~for the preparation of a diagnostic composition.~~

14.(currently amended) The ~~[[use]]~~ composition according to claim 13, wherein said diagnostic composition is utilized in the characterization of melanoma expressing PTPRK_{Gly677→Arg682}.